StreetInsider.com News Articles

Piper Sandler Starts Veracyte, Inc (VCYT) at Overweight

Wed, 15 Jul 2026 04:09:39 -0400

Piper Sandler analyst David Westenberg initiates coverage on Veracyte, Inc (NASDAQ: VCYT) with a Overweight rating and a price target of $66.00.

The analyst comments: “We initiate on VCYT with an OW rating and a PT of $66. The company is a rare cashgenerative dx lab anchored by two dominant genomic classifiers that resolve clinical ambiguity and guide treatment. Afirma risk-stratifies indeterminate thyroid nodules to spare patients unnecessary surgery, and we see it as the top product in the category. Decipher Prostate is the only Simon Level 1B evidence test that quantifies metastatic risk to guide treatment intensity in prostate. The

Piper Sandler Starts Veracyte, Inc (VCYT) at Overweight

Wed, 15 Jul 2026 04:09:39 -0400

Piper Sandler analyst David Westenberg initiates coverage on Veracyte, Inc (NASDAQ: VCYT) with a Overweight rating and a price target of $66.00.

Veracyte, Inc (VCYT) PT Raised to $60 at Canaccord

Tue, 14 Jul 2026 06:42:40 -0400

Canaccord analyst Kyle Mikson raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $60.00 (from $42.00) while maintaining a Hold rating.

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

Thu, 09 Jul 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/wwu2pyd7. A webcast replay will be

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

Thu, 09 Jul 2026 16:05:00 -0400

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/wwu2pyd7. A webcast replay will be

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

Thu, 09 Jul 2026 16:05:00 -0400

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/wwu2pyd7. A webcast replay will be

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

Thu, 09 Jul 2026 16:05:00 -0400

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/wwu2pyd7. A webcast replay will be

Veracyte, Inc (VCYT) PT Raised to $47 at Morgan Stanley

Thu, 09 Jul 2026 08:16:30 -0400

Morgan Stanley analyst Kallum Titchmarsh raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $47.00 (from $37.00) while maintaining a Underweight rating.

Veracyte, Inc (VCYT) PT Raised to $65 at Guggenheim

Mon, 29 Jun 2026 06:55:24 -0400

Guggenheim analyst Subbu Nambi raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $65.00 (from $45.00) while maintaining a Buy rating.

Form 4 VERACYTE, INC. For: Jun 18 Filed by: EASTHAM KARIN

Mon, 22 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260622/26673557.html

Form 4 VERACYTE, INC. For: Jun 18 Filed by: EASTHAM KARIN

Mon, 22 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260622/26673557.html

Form 144 VERACYTE, INC. Filed by: EASTHAM KARIN

Thu, 18 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260618/26666404.html

Form 144 VERACYTE, INC. Filed by: EASTHAM KARIN

Thu, 18 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260618/26666404.html

Form 4 VERACYTE, INC. For: Jun 11 Filed by: Miller Thomas F.